ACR/EULAR 2010 Criteria: The classification criteria for Rheumatoid Arthritis. A score of ≥ 6 is diagnostic of definite RA.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Classification of adult patients with suspected Rheumatoid Arthritis (RA).
Evaluating patients with at least one joint with definite clinical synovitis (swelling).
Standardizing clinical trial enrollment and early DMARD initiation.
Prerequisites
The criteria should only be applied if synovitis is not better explained by another disease (e.g., SLE, Psoriatic Arthritis, Gout, CPPD). If the patient has typical erosions on X-ray, RA can be diagnosed without further scoring.
Section 2
Formula & Logic
Joint Involvement (Maximum 5 pts)
1 large joint
0 pts
2–10 large joints
1 pt
1–3 small joints
2 pts
4–10 small joints
3 pts
> 10 joints (at least 1 small joint)
5 pts
Serology (Maximum 3 pts)
Negative RF and Negative ACPA
0 pts
Low-positive RF or Low-positive ACPA
2 pts
High-positive RF or High-positive ACPA
3 pts
Acute-Phase Reactants (Maximum 1 pt)
Normal CRP and Normal ESR
0 pts
Abnormal CRP or Abnormal ESR
1 pt
Duration of Symptoms (Maximum 1 pt)
< 6 weeks
0 pts
≥ 6 weeks
1 pt
Interpretation
A total score of ≥ 6/10 is required for classification of "Definite RA".
Section 3
Pearls/Pitfalls
Diagnostic Shift
Unlike the 1987 criteria, which prioritized chronic, erosive disease (late-stage RA), the 2010 criteria focus on early detection to prevent joint damage. "High-positive" is defined as > 3x the upper limit of normal (ULN).
Small vs. Large Joints
Small joints: MCP, PIP, MTP (2–5), thumb IP, and wrists.
Large joints: Shoulders, elbows, hips, knees, and ankles.
DIP joints, 1st MTP, and 1st CMC joints are typically excluded (more suggestive of OA).
Limitations
Seronegative RA (Negative RF/ACPA) requires high joint counts to meet classification.
May misclassify other inflammatory arthritides if exclusions are not rigorously applied.
Does not account for symmetric vs. asymmetric patterns, though RA is typically symmetric.
Section 4
Next Steps
Definite RA (Score ≥ 6)
01
Initiate DMARD therapy (Methotrexate is first-line unless contraindicated).
02
Screen for comorbidities (CVD risk, Osteoporosis, ILD).
03
Set "Treat-to-Target" goals (remission or low disease activity).
04
Arrange baseline hand/foot radiographs to monitor for future erosions.
Possible RA (Score < 6)
01
Re-evaluate prospectively if symptoms persist or worsen.
02
Consider MSK Ultrasound or MRI to detect subclinical synovitis.
03
Review differential diagnosis again (e.g., Viral arthritis, Spondyloarthritis).
Disease Activity Tools
CDAI
SDAI
DAS28-ESR/CRP
RAPID3
Section 5
Evidence Appraisal
Primary Reference
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Aletaha D et al. • Arthritis Rheum.. 2010;62(9):2569-81. This study revolutionized rheumatology by shifting the paradigm from treating established joint damage to treating early inflammation.
Validation Data
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: ADRB phase 2 studies.
Funovits J et al. • Ann Rheum Dis.. 2010;Demonstrated high sensitivity and specificity for identifying patients requiring methotrexate therapy within the first year of symptoms.
Section 6
Literature
Consensus Building
The 2010 criteria were developed through a complex process involving a European (EULAR) and North American (ACR) collaboration. The committee used a three-phase approach: a data-driven phase based on actual patient cohorts, a consensus-driven phase using expert scenarios, and a final validation phase.
Modern Rationale
The inclusion of ACPA (anti-cyclic citrullinated peptide antibody) was the most significant biological advancement over the older 1987 system, as it has superior specificity (~95%) and prognostic value for radiographic progression compared to Rheumatoid Factor.
